Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

2023
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2023 3
2024 3
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean hopkin md[au] (4 results)?
The dynamic impact of location and resection on the glioma CSF proteome.
Riviere-Cazaux C, Graser CJ, Warrington AE, Hoplin MD, Andersen KM, Malik N, Palmer EA, Carlstrom LP, Dasari S, Munoz-Casabella A, Ikram S, Ghadimi K, Himes BT, Jusue-Torres I, Sarkaria JN, Meyer FB, Van Gompel JJ, Kizilbash SH, Sener U, Michor F, Campian JL, Parney IF, Burns TC. Riviere-Cazaux C, et al. Among authors: hoplin md. medRxiv [Preprint]. 2024 May 16:2024.05.15.24307463. doi: 10.1101/2024.05.15.24307463. medRxiv. 2024. PMID: 38798641 Free PMC article. Preprint.
Cerebrospinal fluid 2-hydroxyglutarate as a monitoring biomarker for IDH-mutant gliomas.
Riviere-Cazaux C, Lacey JM, Carlstrom LP, Laxen WJ, Munoz-Casabella A, Hoplin MD, Ikram S, Zubair AB, Andersen KM, Warrington AE, Decker PA, Kaufmann TJ, Campian JL, Eckel-Passow JE, Kizilbash SH, Tortorelli S, Burns TC. Riviere-Cazaux C, et al. Among authors: hoplin md. Neurooncol Adv. 2023 May 11;5(1):vdad061. doi: 10.1093/noajnl/vdad061. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37313502 Free PMC article. No abstract available.
Cerebrospinal fluid 2-hydroxyglutarate (2-HG) as a monitoring biomarker for IDH-mutant gliomas.
Riviere-Cazaux C, Lacey JM, Carlstrom LP, Laxen WJ, Munoz-Casabella A, Hoplin MD, Ikram S, Zubair AB, Andersen KM, Warrington AE, Decker PA, Kaufmann TJ, Campian JL, Eckel-Passow JE, Kizilbash SH, Tortorelli S, Burns TC. Riviere-Cazaux C, et al. Among authors: hoplin md. medRxiv [Preprint]. 2023 Mar 2:2023.03.01.23286412. doi: 10.1101/2023.03.01.23286412. medRxiv. 2023. Update in: Neurooncol Adv. 2023 May 11;5(1):vdad061. doi: 10.1093/noajnl/vdad061 PMID: 36909488 Free PMC article. Updated. Preprint.
Longitudinal glioma monitoring via cerebrospinal fluid cell-free DNA.
Riviere-Cazaux C, Dong X, Mo W, Kumar R, Dai C, Carlstrom LP, Munoz-Casabella A, Ghadimi K, Nesvick CL, Andersen KM, Hoplin MD, Canaday N, Jusue-Torres I, Malik N, Campian JL, Ruff MW, Uhm JH, Eckel-Passow JE, Kaufmann TJ, Routman DM, Kizilbash SH, Sener U, Warrington AE, Jenkins RB, Du P, Jia S, Burns TC. Riviere-Cazaux C, et al. Among authors: hoplin md. Clin Cancer Res. 2024 Dec 23. doi: 10.1158/1078-0432.CCR-24-1814. Online ahead of print. Clin Cancer Res. 2024. PMID: 39715486
A field resource for the glioma cerebrospinal fluid proteome: impacts of resection and location on biomarker discovery.
Riviere-Cazaux C, Graser CJ, Warrington AE, Hoplin MD, Andersen KM, Malik N, Palmer EA, Carlstrom LP, Dasari S, Munoz-Casabella A, Ikram S, Ghadimi K, Himes BT, Jusue-Torres I, Sarkaria JN, Meyer FB, Van Gompel JJ, Kizilbash SH, Sener U, Michor F, Campian JL, Parney IF, Burns TC. Riviere-Cazaux C, et al. Among authors: hoplin md. Neuro Oncol. 2024 Dec 30:noae277. doi: 10.1093/neuonc/noae277. Online ahead of print. Neuro Oncol. 2024. PMID: 39786485